Galecto, Inc.

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, ONC has a market cap of 29.4B. Regarding current trading prices, DMRA is priced at $18.14, while ONC trades at $282.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas ONC's P/E ratio is 111.90. In terms of profitability, DMRA's ROE is -1.47%, compared to ONC's ROE of +0.07%. Regarding short-term risk, DMRA is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check ONC's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, DMRA is priced at $18.14, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas WBA's P/E ratio is -1.64. In terms of profitability, DMRA's ROE is -1.47%, compared to WBA's ROE of -0.39%. Regarding short-term risk, DMRA is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check WBA's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, DFTX has a market cap of 1.8B. Regarding current trading prices, DMRA is priced at $18.14, while DFTX trades at $18.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas DFTX's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to DFTX's ROE of -0.84%. Regarding short-term risk, DMRA is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check DFTX's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, DMRA is priced at $18.14, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas HROWL's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to HROWL's ROE of -0.10%. Regarding short-term risk, DMRA is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check HROWL's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, DMRA is priced at $18.14, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas HROWM's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to HROWM's ROE of -0.10%. Regarding short-term risk, DMRA is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check HROWM's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, LFMDP has a market cap of 1B. Regarding current trading prices, DMRA is priced at $18.14, while LFMDP trades at $23.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas LFMDP's P/E ratio is -10.20. In terms of profitability, DMRA's ROE is -1.47%, compared to LFMDP's ROE of +2.82%. Regarding short-term risk, DMRA is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check LFMDP's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, CGEM has a market cap of 773.8M. Regarding current trading prices, DMRA is priced at $18.14, while CGEM trades at $13.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas CGEM's P/E ratio is -3.81. In terms of profitability, DMRA's ROE is -1.47%, compared to CGEM's ROE of -0.46%. Regarding short-term risk, DMRA is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check CGEM's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, ATAI has a market cap of 658.3M. Regarding current trading prices, DMRA is priced at $18.14, while ATAI trades at $3.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas ATAI's P/E ratio is -4.20. In terms of profitability, DMRA's ROE is -1.47%, compared to ATAI's ROE of -1.08%. Regarding short-term risk, DMRA is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check ATAI's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, HITI has a market cap of 196.8M. Regarding current trading prices, DMRA is priced at $18.14, while HITI trades at $2.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas HITI's P/E ratio is -4.98. In terms of profitability, DMRA's ROE is -1.47%, compared to HITI's ROE of -0.41%. Regarding short-term risk, DMRA is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check HITI's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, LFMD has a market cap of 187.7M. Regarding current trading prices, DMRA is priced at $18.14, while LFMD trades at $4.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas LFMD's P/E ratio is -15.60. In terms of profitability, DMRA's ROE is -1.47%, compared to LFMD's ROE of +2.82%. Regarding short-term risk, DMRA is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check LFMD's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, DMRA is priced at $18.14, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas LFLY's P/E ratio is -0.04. In terms of profitability, DMRA's ROE is -1.47%, compared to LFLY's ROE of +0.25%. Regarding short-term risk, DMRA is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check LFLY's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, YI has a market cap of 59.4M. Regarding current trading prices, DMRA is priced at $18.14, while YI trades at $6.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas YI's P/E ratio is -2.40. In terms of profitability, DMRA's ROE is -1.47%, compared to YI's ROE of +0.11%. Regarding short-term risk, DMRA is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check YI's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, PETS has a market cap of 51.8M. Regarding current trading prices, DMRA is priced at $18.14, while PETS trades at $2.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas PETS's P/E ratio is -0.78. In terms of profitability, DMRA's ROE is -1.47%, compared to PETS's ROE of -1.22%. Regarding short-term risk, DMRA is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check PETS's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, DMRA is priced at $18.14, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas RAD's P/E ratio is -0.05. In terms of profitability, DMRA's ROE is -1.47%, compared to RAD's ROE of +2.76%. Regarding short-term risk, DMRA is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check RAD's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, POM has a market cap of 34.8M. Regarding current trading prices, DMRA is priced at $18.14, while POM trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas POM's P/E ratio is -6.51. In terms of profitability, DMRA's ROE is -1.47%, compared to POM's ROE of +0.07%. Regarding short-term risk, DMRA is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check POM's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, RNTX has a market cap of 32.6M. Regarding current trading prices, DMRA is priced at $18.14, while RNTX trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas RNTX's P/E ratio is -0.42. In terms of profitability, DMRA's ROE is -1.47%, compared to RNTX's ROE of -2.17%. Regarding short-term risk, DMRA is more volatile compared to RNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check RNTX's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, KYNB has a market cap of 28.8M. Regarding current trading prices, DMRA is priced at $18.14, while KYNB trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas KYNB's P/E ratio is -0.55. In terms of profitability, DMRA's ROE is -1.47%, compared to KYNB's ROE of -1.62%. Regarding short-term risk, DMRA is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check KYNB's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, DMRA is priced at $18.14, while MEDS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas MEDS's P/E ratio is -0.31. In terms of profitability, DMRA's ROE is -1.47%, compared to MEDS's ROE of -0.26%. Regarding short-term risk, DMRA is more volatile compared to MEDS. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check MEDS's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, DMRA is priced at $18.14, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas CJJD's P/E ratio is -0.46. In terms of profitability, DMRA's ROE is -1.47%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, DMRA is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check CJJD's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, MSLE has a market cap of 9.3M. Regarding current trading prices, DMRA is priced at $18.14, while MSLE trades at $8.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas MSLE's P/E ratio is 2.82. In terms of profitability, DMRA's ROE is -1.47%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, DMRA is less volatile compared to MSLE. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check MSLE's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, NEUP has a market cap of 8.6M. Regarding current trading prices, DMRA is priced at $18.14, while NEUP trades at $4.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas NEUP's P/E ratio is -6.65. In terms of profitability, DMRA's ROE is -1.47%, compared to NEUP's ROE of -15.38%. Regarding short-term risk, DMRA is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check NEUP's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, DMRA is priced at $18.14, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas SSY's P/E ratio is -2.86. In terms of profitability, DMRA's ROE is -1.47%, compared to SSY's ROE of -0.18%. Regarding short-term risk, DMRA is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check SSY's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, HKPD has a market cap of 7M. Regarding current trading prices, DMRA is priced at $18.14, while HKPD trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas HKPD's P/E ratio is 3.74. In terms of profitability, DMRA's ROE is -1.47%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, DMRA is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check HKPD's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, AIXC has a market cap of 6.4M. Regarding current trading prices, DMRA is priced at $18.14, while AIXC trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas AIXC's P/E ratio is 0.44. In terms of profitability, DMRA's ROE is -1.47%, compared to AIXC's ROE of -0.73%. Regarding short-term risk, DMRA is more volatile compared to AIXC. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check AIXC's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, DMRA is priced at $18.14, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas MDVL's P/E ratio is -0.05. In terms of profitability, DMRA's ROE is -1.47%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, DMRA is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check MDVL's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, BGMSP has a market cap of 2.8M. Regarding current trading prices, DMRA is priced at $18.14, while BGMSP trades at $2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas BGMSP's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to BGMSP's ROE of -7.22%. Regarding short-term risk, DMRA is less volatile compared to BGMSP. This indicates potentially lower risk in terms of short-term price fluctuations for DMRA.Check BGMSP's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, DMRA is priced at $18.14, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas ATNFW's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, DMRA is more volatile compared to ATNFW. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check ATNFW's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, BGMS has a market cap of 1.8M. Regarding current trading prices, DMRA is priced at $18.14, while BGMS trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas BGMS's P/E ratio is -0.07. In terms of profitability, DMRA's ROE is -1.47%, compared to BGMS's ROE of -1.87%. Regarding short-term risk, DMRA is more volatile compared to BGMS. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check BGMS's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, NVOH has a market cap of 1.8M. Regarding current trading prices, DMRA is priced at $18.14, while NVOH trades at $20.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas NVOH's P/E ratio is 10.42. In terms of profitability, DMRA's ROE is -1.47%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, DMRA is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check NVOH's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, DMRA is priced at $18.14, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas AZNH's P/E ratio is 38.35. In terms of profitability, DMRA's ROE is -1.47%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, DMRA is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check AZNH's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, DMRA is priced at $18.14, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, DMRA's ROE is -1.47%, compared to LFLYW's ROE of +0.25%. Regarding short-term risk, DMRA is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check LFLYW's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, DMRA is priced at $18.14, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas BIMI's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, DMRA is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check BIMI's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, DMRA is priced at $18.14, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas ESRX's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, DMRA is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check ESRX's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, DMRA is priced at $18.14, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas IPXL's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, DMRA is more volatile compared to IPXL. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check IPXL's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, POZN has a market cap of 0. Regarding current trading prices, DMRA is priced at $18.14, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas POZN's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to POZN's ROE of +0.61%. Regarding short-term risk, DMRA is more volatile compared to POZN. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check POZN's competition here

DMRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DMRA stands at 1.1B. In comparison, CPD has a market cap of 0. Regarding current trading prices, DMRA is priced at $18.14, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DMRA currently has a P/E ratio of -1.50, whereas CPD's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.47%, compared to CPD's ROE of N/A. Regarding short-term risk, DMRA is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for DMRA.Check CPD's competition here